Can KUBTEC Scientific lower the barrier to image-guided radiotherapy in cancer research?
Preclinical IGRT is powerful but costly. KUBTEC Scientific’s XCELL TomoRad tests whether access, speed, and targeting can finally align.
Soley Therapeutics shows early tumor selectivity for STX-6398, but can CKAP2 modulation scale?
Soley Therapeutics unveiled AACR 2026 data for STX-6398. Read why CKAP2 modulation could open a new path in oncology.